Navigation Links
Sangui Bio Tech International Inc. - Over 500 Customers: Granulox Sales Ahead of Planning

WITTEN, Germany, August 13, 2012 /PRNewswire/ --

SastoMed GmbH, global licensee of the Sangui patented wound spray, has submitted the announced report covering the first 100 days of Granulox product sales. The report is available on Its results meet and in some parts considerably exceed the expectations which were directed at the joint venture company by SanguiBioTech GmbH as the licenser. SastoMed assumes that the initial investments will have amortized by 2014. Before that already, Sangui will participate in each Euro of revenue in Germany and abroad and will profit by the considerable growth dynamic.

The sales strategy is based on an exemplary assessment of the complex health market the accuracy of which is underpinned by the presented sales progress. Until July 31, the sales force had arranged for almost 4,800 meetings and handed over more than 1,000 samples. After no more than 100 days about 500 customers have been registered as actively purchasing the product. With this customer base SastoMed are ahead of planning. In addition, the sales team is present at most conferences, trade shows or workshops dedicated to wound management. The communication with opinion leaders and the expert public will now be complemented by an extensive advertising campaign in the consumer media and the internet. Still, personal contact and practical experience are decisive to convince the users.  

As had been expected according to the findings of Sangui research and development, impressive documentation of successful wound treatments underline the excellent efficacy of Granulox in everyday health care practice. For some time it had been known among medical researchers that there is a correlation between hypoxia and impeded wound healing. Thanks to its research focus on oxygen Sangui was the first and only company to draw the right conclusions and to develop a hemoglobin based technology which actually and effectively enhances the oxygen supply and thus supports wound therapies.

The growing dynamics in penetrating the market will even increase further next year according to SastoMed: Overall another 5,000 doctors and 500 hospitals are planned to be gained to regularly administer Granulox in Germany alone. At the same time internationalizing the business will move up on the agenda. The current positive experiences made in Germany will among others also lead to entrusting the leadership in operating sales in Mexico to SastoMed - for the sake of a consistent market appearance and in accordance with the Mexican partners. In parallel, market entry in Austria, the United Kingdom and Turkey are under preparation. Additional European markets are planned to be addressed in 2014. The international business will be directed by a top marketing and sales manager with international track record. More details will be disclosed after the signing of the final articles of employment.

Hubertus Schmelz, Managing Director of SanguiBioTech GmbH, was impressed by these preliminary statements: "We at Sangui are particularly proud of the fact that our yearlong focus on this technology was the right move. We are especially glad to obtain such a positive response from competent experts, who confirm our great expectations. And we are delighted to see how many patients now experience the benefits of Granulox treatment. Our strategic decision to transfer marketing and sales of the Sangui developed technology to highly professional partners has proven to be the best possible choice. We support this intense growth course also on the financial side and intend to push-start the international activities. We can foresee that beginning end of this year but increasingly so over the years to come the positive cash flow from the joint venture company will more than justify our decisions."    

Further inquiry note:
Dr. Joachim Fleing
Fon: +49(179)7963472
Fax: +49(2302)915-191

Sangui Bio Tech International Inc. 
Alfred-Herrhausen-Strasse 44              
D-58455 Witten
phone:  +49(0)2302-915-200
FAX:    +49(0)2302-915-191
sector:  Biotechnology
ISIN: DE0000906757
stockmarkets: free trade: Hamburg, New York  

SOURCE Sangui Bio Tech International Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. CE Mark Granted for Wound Spray Based on Sangui Patent
2. Mexican State of Tamaulipas Starts Training Doctors in Sangui Wound Management
3. Yongye International Announces Second Quarter 2012 Financial Results
4. Yongye International to Report Second Quarter 2012 Financial Results on August 9, 2012
5. Dyadic International to Announce Second Quarter 2012 Financial Results and Host Conference Call on Monday, August 13, 2012
6. SRI International Researchers Developing Bioadhesive Gel to Protect Women from HIV and HSV Infections
7. Elsevier Launches International Journal for Parasitology: Parasites and Wildlife
8. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
9. Bunker Hill Community College Student Speaks at 2012 BIO International Convention
10. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
11. Promoting the States Quality of Life, New Jersey Symphony Orchestra to Perform at BIO International Convention
Post Your Comments:
(Date:11/25/2015)... Studies reveal the differences in species of bacteria ... for more effective treatment for one of the most commonly ... --> --> Gum disease is one ... relatively little was understood about the bacteria associated with it ... researchers from the WALTHAM Centre for Pet Nutrition together with ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the signing ... AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology:
(Date:11/16/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced expansion of its TDDI product portfolio with ... and display driver integration (TDDI) solutions designed to ... TDDI products add to the previously-announced TD4300 ... resolution), and TD4322 (FHD resolution) solutions. All four ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):